Geron (GERN) Enterprise Value (2010 - 2026)
Geron (GERN) posted Enterprise Value of -$292.2 million for Q1 2026, up 12.58% sequentially from -$334.3 million in Q4 2025, and up 7.23% YoY from -$272.5 million in Q1 2025.
Geron (GERN) Enterprise Value (2010 - 2026) Analysis & Trends
Geron has reported Enterprise Value for 17 years, with the latest figure at -$292.2 million in Q1 2026.
- Quarterly Enterprise Value rose 7.23% year-over-year to -$292.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$292.2 million (up 7.23% YoY) and the FY2025 annual result came in at -$334.3 million, down 1.48% from the prior year.
- Enterprise Value improved to -$292.2 million in Q1 2026 per GERN's latest filing, from -$334.3 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$134.0 million in Q3 2022 and troughed at -$443.0 million in Q1 2024.
- A 5-year average of -$295.9 million and a median of -$313.5 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value slumped 133.89% in 2023, then grew 28.9% in 2025.
- Over 5 years, Enterprise Value stood at -$172.7 million in 2022, then sank by 93.17% to -$333.7 million in 2023, then gained by 1.29% to -$329.4 million in 2024, then decreased by 1.48% to -$334.3 million in 2025, then grew by 12.58% to -$292.2 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$292.2 million, -$334.3 million, and -$380.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 2.12 Bn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | -300.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -300.85 Mn |
| Mar 31, 2026 | -292.23 Mn |
| Dec 31, 2025 | -334.29 Mn |
| Sep 30, 2025 | -380.53 Mn |
| Jun 30, 2025 | -312.12 Mn |
| Mar 31, 2025 | -315.00 Mn |
| Dec 31, 2024 | -329.41 Mn |
| Sep 30, 2024 | -281.28 Mn |
| Jun 30, 2024 | -362.73 Mn |
| Mar 31, 2024 | -443.05 Mn |
| Dec 31, 2023 | -333.70 Mn |
| Sep 30, 2023 | -313.53 Mn |
| Jun 30, 2023 | -371.38 Mn |
| Mar 31, 2023 | -268.33 Mn |
| Dec 31, 2022 | -172.75 Mn |
| Sep 30, 2022 | -134.05 Mn |
| Jun 30, 2022 | -219.29 Mn |
| Mar 31, 2022 | -166.67 Mn |
| Dec 31, 2021 | -149.22 Mn |
| Sep 30, 2021 | -147.45 Mn |